These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 9352708

  • 1. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?
    Herr HW.
    Br J Urol; 1997 Oct; 80(4):653-7. PubMed ID: 9352708
    [Abstract] [Full Text] [Related]

  • 2. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
    Aprikian AG, Herr HW, Bajorin DF, Bosl GJ.
    Cancer; 1994 Aug 15; 74(4):1329-34. PubMed ID: 8055456
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
    Nakamura T, Oishi M, Ueda T, Fujihara A, Nakanishi H, Kamoi K, Naya Y, Hongo F, Okihara K, Miki T.
    Int J Urol; 2015 Jul 15; 22(7):663-8. PubMed ID: 25847721
    [Abstract] [Full Text] [Related]

  • 4. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
    Beck SD, Foster RS, Bihrle R, Ulbright T, Koch MO, Wahle GR, Einhorn LH, Donohue JP.
    J Urol; 2002 Oct 15; 168(4 Pt 1):1402-4. PubMed ID: 12352402
    [Abstract] [Full Text] [Related]

  • 5. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M, Malavaud B, Bayoud Y, Sebe P, Hoepffner JL, Salomon L, Houlgatte A, Pignot G, Rigaud J, Fléchon A, Pfister C, Rouprêt M, Soulié M, Méjean A, Durand X.
    J Surg Oncol; 2016 Dec 15; 114(8):992-996. PubMed ID: 27859263
    [Abstract] [Full Text] [Related]

  • 6. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis.
    Nitta S, Kawai K, Kimura T, Kandori S, Kawahara T, Kojima T, Nishiyama H.
    Int J Urol; 2021 Aug 15; 28(8):840-847. PubMed ID: 34085325
    [Abstract] [Full Text] [Related]

  • 7. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient?
    Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan LD.
    Br J Urol; 1998 Feb 15; 81(2):295-300. PubMed ID: 9488075
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer.
    Fosså SD, Ous S, Lien HH, Stenwig AE.
    J Urol; 1989 Mar 15; 141(3):557-9. PubMed ID: 2918591
    [Abstract] [Full Text] [Related]

  • 10. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD.
    Cancer; 1996 Aug 01; 78(3):480-6. PubMed ID: 8697394
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
    Herr HW, Toner GC, Geller NL, Bosl GJ.
    Eur Urol; 1991 Aug 01; 19(1):1-5. PubMed ID: 1848821
    [Abstract] [Full Text] [Related]

  • 13. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
    Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C.
    Eur J Cancer; 1997 May 01; 33(6):843-7. PubMed ID: 9291803
    [Abstract] [Full Text] [Related]

  • 14. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
    Paffenholz P, Pfister D, Heidenreich A.
    Urologe A; 2016 May 01; 55(5):632-40. PubMed ID: 26820659
    [Abstract] [Full Text] [Related]

  • 15. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
    Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld J.
    Cancer; 2007 Feb 01; 109(3):528-35. PubMed ID: 17177200
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery.
    Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP.
    J Urol; 2009 Jun 01; 181(6):2526-32. PubMed ID: 19371895
    [Abstract] [Full Text] [Related]

  • 17. [A case of teratoma of the testis with retroperitoneal lymph nodes involved with malignant teratoma after chemotherapy].
    Muraki J, Nakazono M.
    Nihon Hinyokika Gakkai Zasshi; 1993 Dec 01; 84(12):2162-5. PubMed ID: 7508531
    [Abstract] [Full Text] [Related]

  • 18. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
    Miranda Ede P, Abe DK, Nesrallah AJ, dos Reis ST, Crippa A, Srougi M, Dall'Oglio MF.
    World J Surg Oncol; 2012 Sep 28; 10():203. PubMed ID: 23021209
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.